Prokidney announces positive interim data from rmcl-002 phase 2 clinical trial of renal autologous cell therapy (react®) for diabetic ckd and provides corporate updates

Updated positive interim phase 2 data demonstrate potential efficacy of react® to preserve kidney function in moderate and high-risk diabetic ckd patients
PROK Ratings Summary
PROK Quant Ranking